Germline Mutations in Patients With Early-Onset Prostate Cancer.

Authors

Tang Tang
Xintao Tan
Ze Wang
Shuo Wang
Yapeng Wang
Jing Xu
Xiajie Wei
Dianzheng Zhang, Philadelphia College of Osteopathic MedicineFollow
Qiuli Liu
Jun Jiang

Document Type

Article

Publication Date

1-1-2022

Abstract

Objective: To investigate the inherited mutations and their association with clinical features and treatment response in young-onset prostate cancer patients.

Method: Targeted gene sequencing on 139 tumor susceptibility genes was conducted with a total of 24 patients diagnosed with PCa under the age of 63 years old. Meanwhile, the related clinical information of those patients is collected and analyzed.

Results: Sixty-two germline mutations in 45 genes were verified in 22 patients.

Conclusion: Mutations in DRGs are more prevalent in early-onset PCa with advanced clinical stages, and these patients had shorter progression-free survival. ADT Combined with either radiotherapy or chemotherapy may be effective in treating PCa caused by HRR-related gene mutations.

Publication Title

Frontiers in Oncology

Volume

12

PubMed ID

35734583

Comments

This article was published in Frontiers in Oncology, Volume 12.

The published version is available at https://doi.org/10.3389/fonc.2022.826778.

Copyright © 2022 Tang, Tan, Wang, Wang, Wang, Xu, Wei, Zhang, Liu and Jiang. CC-BY 4.0.

Recommended Citation

Tang, Tang; Tan, Xintao; Wang, Ze; Wang, Shuo; Wang, Yapeng; Xu, Jing; Wei, Xiajie; Zhang, Dianzheng; Liu, Qiuli; and Jiang, Jun, "Germline Mutations in Patients With Early-Onset Prostate Cancer." (2022). PCOM Scholarly Works. 2161.
https://digitalcommons.pcom.edu/scholarly_papers/2161